Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2022.
Akoya reported the following preliminary financial results for the fourth quarter and full year 2022, which remain subject to quarter end closing adjustments:
Revenue for the fourth quarter of 2022 is expected to be between $20.7 million and $21.2 million, as compared to $16.2 million for the corresponding quarter of last year
For the fiscal year of 2022, revenue is expected to be between $74.3 million and $74.8 million, as compared to $54.9 million for fiscal year 2021
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.